TNFSF10 and prostate carcinoma: In the most recent studies, ES/TRAIL liposomes demonstrated a potent synergistic apoptotic effect in prostate cancer cells with the liposomal form of piperlongumine [54] and killed CTCs and CTC clusters in blood samples from prostate cancer patients under flow conditions [55], asserting that liposomal TRAIL can be a promising adjuvant therapy.